Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Of The Date Of 44Th Annual General Meeting And Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 We have to inform you that the 44th Annual General Meeting (AGM) of Members of the Company is scheduled to be held on Tuesday, September 27, 2022 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM"). The copy of the notice will be sent to you in due course. Pursuant to the Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Wednesday, September 14, 2022 to Tuesday, September 27, 2022 (both days inclusive) for the purpose of the AGM and. determining the names of the eligible Members for equity dividend.
24-08-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Update On The Company''s Monroe, North Carolina (USA) Facility

 Update on the Company''s Monroe, North Carolina (USA) Facility
23-08-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, enclosed are the copies of newspaper advertisement pertaining to Notice of transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF) Authority.
22-08-2022

US biz growth in FY23 expected to be flat or low single-digit: Glenmark

 Glenmark Pharmaceuticals expects growth of its US business to be flat or at low single digit in 2022-23 amid challenges of price erosion and unpredictable product approval by the USFDA, according to a senior company official. The company's North America business, including the US, recorded a revenue of Rs 662.8 crore in April-June 2022 as compared to Rs 787.8 crore in the year-ago period, down 15.9 per cent. It accounted for 23.9 per cent of consolidated sales in the quarter. In the first quarter, Glenmark's consolidated revenues from operations stood at Rs 2,777.3 crore as against Rs 2,964.9 crore in the corresponding period last year, a decline of 6.3 per cent. "We are looking at flat to low single-digit growth in the US for FY23 compared to FY22," Glenmark Pharmaceuticals Ltd CEO - Global Formulations business Brendan O' Grady told analysts. He was responding to a query on the outlook for the US business and reasons for decline in sales in the country. "The US business is...
22-08-2022

Accumulate Glenmark Pharma; target of Rs 433: KR Choksey

 KR Choksey recommended accumulate rating on Glenmark Pharma with a target price of Rs 433 in its research report dated August 16, 2022.
17-08-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Further to our letter dated 01st August, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, August 12, 2022 for the quarter ended June 30, 2022 has been uploaded on the Company's website.
17-08-2022

Neutral Glenmark Pharma; target of Rs 420: Motilal Oswal

 Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 420 in its research report dated August 12, 2022.
15-08-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Audio recording of Q1 of FY 2022-23 Earnings Call
12-08-2022

Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore

 Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent
10-08-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results Standalone And Consolidated For The First Quarter Ended June 30, 2022

 Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First Quarter ended June 30, 2022. The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.10 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company
10-08-2022
Next Page
Close

Let's Open Free Demat Account